-
Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials
•
Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for the third quarter of its 2023 fiscal year, which ended on June 30. The company reported global revenues of EUR 5.2 billion (USD 5.6 billion), marking a 3.6% year-on-year (YOY) growth in constant exchange rate…
-
Biogen Inc. to Acquire Reata Pharmaceuticals in $7.3 Billion Deal
•
US-based Biogen Inc., (NASDAQ: BIIB) has announced that it has reached an agreement to fully acquire compatriot firm Reata Pharmaceuticals Inc., (NASDAQ: RETA) in a cash deal valued at USD 172.50 per share, totaling USD 7.3 billion. The acquisition is anticipated to be completed in the fourth quarter of 2023.…
-
Pfizer Inc. Reports Q2 2023 Revenues, Signals Shift Beyond COVID-19 Products
•
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the second quarter of 2023, reporting revenues of USD 12.7 billion over the three months, marking a year-on-year (YOY) decrease of 53%. The decline is attributed to the loss of sales from Paxlovid (nirmatrelvir, ritonavir) and Comirnaty…
-
EQRx Inc. to be Acquired by Revolution Medicines in All-Stock Transaction
•
US-based EQRx Inc. (NASDAQ: EQRX) has revealed that a definitive agreement has been signed for the company to be fully acquired by US-based Revolution Medicines (NASDAQ: RVMD). The transaction will be executed as an all-stock deal, with Revolution issuing shares to EQRx shareholders, anticipating the acquisition of over USD 1…
-
GSK Partners with Zuellig Pharma for Vaccine Distribution and Cold-Chain Management in Asia-Pacific
•
GlaxoSmithKline (GSK; NYSE: GSK), a leading global vaccine manufacturer, has signed an agreement with Philippines-based Zuellig Pharma to provide warehousing and distribution services, with a focus on cold-chain management for GSK’s vaccines in Singapore. This strategic partnership will establish a vaccine distribution hub serving 13 markets across the Asia-Pacific region.…
-
Luye Pharma’s Parkinson’s Disease Treatment LY03003 Receives NMPA Review Acceptance
•
Luye Pharma Group (HKG: 2186) has announced that the National Medical Products Administration (NMPA) has accepted a market filing for its once-weekly rotigotine extended-release microspheres for injection (LY03003), indicated for the treatment of Parkinson’s disease (PD), with a priority review status. LY03003: A Breakthrough in Dopamine StimulationHailed as the world’s…
-
Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements with a strategic business partner in Egypt and Pakistan pharmaceutical company Searle Co Ltd. These agreements grant local rights to Mabwell’s denosumab biosimilars, MAILISHU and 9MW0321. Denosumab Biosimilars and Their Impact on Fracture Risk ReductionDenosumab,…
-
GeneMind Biosciences Secures RMB 400 Million in Series C Financing to Expand Gene Testing
•
Shenzhen-based DNA sequencer specialist, GeneMind Biosciences Co., Ltd, has reportedly raised RMB 400 million in a Series C financing round. The round was led by Kingmed Diagnostics and Guoxin Investment, with contributions from Shenzhen Hi-tech Investment and Venture Capital, Guochuang Zhiyuan, Changzhou Shuangye Venture Capital, and Cai Xin Capital. The…
